Endra Life Sciences Inc Stock Price, News & Analysis

ENDRA Life Sciences (NASDAQ: NDRA) reported preliminary results from a single-site feasibility study showing its 2025 optimized TAEUS Liver device quantifies liver fat fraction closely aligned with MRI‑PDFF, the imaging gold standard.

Key metrics: 40 subjects (BMI 21–47), Deming regression slope=1 and intercept=0 within 95% CIs, Pearson r=0.89, >90% of subjects within a 5% error margin and average error ~3%. ENDRA plans FDA pre‑submission meetings and a pivotal study; a second feasibility study is underway in Canada.

ENDRA Life Sciences (Nasdaq: NDRA) reported business and Q3 2025 results on November 17, 2025, highlighting financing, balance-sheet actions and clinical progress for its TAEUS® liver imaging device.

Key facts: the company closed a PIPE that generated gross proceeds of approximately $4.9 million on October 23, 2025, with potential additional proceeds of $9.5 million via warrant exercises; regained Nasdaq compliance with Rule 5550(b)(1); reduced cash burn from operations by 30% to $1.2 million in Q3 2025; Q3 operating expenses were $1.4 million versus $1.5 million a year ago; cash and equivalents were $0.8 million at September 30, 2025; and the company completed a single-site clinical feasibility study of the redesigned TAEUS® device with results to be released soon.

ENDRA Life Sciences (Nasdaq: NDRA) has commenced staking its holdings of HYPE, the native token of the Hyperliquid ecosystem, as part of a digital asset treasury strategy announced on November 13, 2025. Guided by ARCA Investment Management and using institutional custody and staking services from Anchorage Digital, ENDRA deployed its HYPE position into a secure staking solution following its initial HYPE investment on October 23, 2025.

The company says staking will generate network rewards, support Hyperliquid network security and decentralization, and provide strategic access to potential governance and DeFi opportunities while aligning with its disciplined treasury management approach.

ENDRA Life Sciences (Nasdaq: NDRA) closed a private placement financing that generated gross proceeds of approximately $4.9 million with potential for up to an additional $9.5 million from warrant exercises. Concurrently, the company launched a digital asset treasury strategy and acquired 78,863.1 HYPE tokens, valued at approximately $3.0 million as of October 21, 2025.

The DAT strategy targets long-term token exposure plus active yield techniques (options overlays, staking, DeFi participation) with trade‑ and portfolio‑level risk controls, aiming to grow tokens‑per‑share, generate reinvestable income, and create optionality for crypto‑related M&A and capital activities. Lucid Capital Markets acted as sole placement agent.

ENDRA Life Sciences (Nasdaq: NDRA) announced $4.9 million in committed proceeds from an at-market private placement to fund a new digital asset treasury (DAT) strategy managed with Arca, and intends to appoint Arca CIO Jeff Dorman to its Digital Asset Advisory Board.

The purchase agreement covers 744,340 shares (or pre-funded warrants) and accompanying warrants to buy up to 1,488,680 shares, sold at a combined price of $6.57. Warrants are exercisable immediately at $6.32 and expire in five years; pre-funded warrants carry a $0.0001 exercise price. If all warrants are exercised, gross proceeds could reach $14.4 million. Majority of net proceeds will go to DAT operations and crypto accumulation; remaining proceeds to complete the TAEUS pilot validation imaging study for MASLD/MASH.

ENDRA Life Sciences (NASDAQ: NDRA), developer of Thermo-Acoustic Enhanced UltraSound (TAEUS®), reported Q2 2025 financial results and provided key business updates. The company has made significant progress in its TAEUS Liver system development, with initial testing showing major accuracy improvements against MRI-PDFF measurements.

ENDRA plans to conduct a 250-subject multisite clinical trial for FDA De Novo submission by year-end. The company has expanded its patent portfolio to 85 issued patents globally and implemented substantial cost reductions, resulting in a 42% decrease in Q2 operating expenses to $1.2 million. Cash position stands at $1.8 million as of June 30, 2025, with quarterly cash burn reduced to $1.1 million.

ENDRA Life Sciences (NDRA) has announced significant progress in its multisite pilot study for the TAEUS Liver system, identifying key enhancements to improve diagnostic accuracy and repeatability compared to MRI standards. The study, involving over 100 subjects, has led to improvements in probe design and proprietary algorithms. These enhancements are being implemented before the FDA De Novo pivotal study. The company plans to expand its clinical pilot study across the U.S. and Canada to validate these improvements. ENDRA's revised strategy includes conducting a prospective pivotal study with approximately 250 patients, moving away from their previous approach of using limited retrospective data. This comprehensive approach aims to strengthen their FDA De Novo submission and establish a competitive position in the liver imaging market.

ENDRA Life Sciences (NASDAQ: NDRA) announced a strategic pivot focusing on metabolic disease management through its TAEUS® Liver system, a point-of-care diagnostic device for steatotic liver disease (SLD). The company targets four key markets: pharmaceutical companies, concierge medical practices, specialized clinics, and primary care providers. ENDRA is developing a next-generation TAEUS system with AI enhancements and plans a revised FDA De Novo submission involving a 250-subject multicenter study. The company will offer the device through a subscription model. Financial results show improved efficiency with Q1 2025 cash burn reduced to $1.2M from $1.7M in Q1 2024, and operating expenses decreased by nearly 50% to $1.5M. Net loss improved to $1.0M from $2.8M year-over-year. As of April 30, 2025, ENDRA had $2.5M in cash after raising $0.8M through its ATM facility.

ENDRA Life Sciences (NASDAQ: NDRA) announced a strategic pivot for its TAEUS® (Thermo-Acoustic Enhanced UltraSound) system, focusing on early detection and management of metabolic diseases in patients using GLP-1 drugs and MASH therapies.

The company is repositioning TAEUS as a biomarker solution for steatotic liver disease (SLD), which affects over 2 billion people globally and one-third of the U.S. population. The new strategy targets four key markets: pharmaceutical companies, concierge medical practices, bariatric clinics, and primary care practices.

Key initiatives include: redesigning TAEUS to be more accurate and user-friendly with AI features, introducing a subscription-based sales model with no upfront costs, and expanding applications beyond liver health to include temperature monitoring for ablation therapies and vascular perfusion.